Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02714218 · ClinicalTrials.gov registry record · Phase 3
A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 387
- Enrollment target
NCT02714218 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 387 participants.
The verdict
NCT02714218, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 387 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate two different dose combinations of nivolumab and ipilimumab in the treatment of melanoma.
Interventions
- BIOLOGICAL Nivolumab 3 mg/kg IV
- BIOLOGICAL Ipilimumab 1 mg/kg IV
- BIOLOGICAL Nivolumab 1 mg/kg IV
- BIOLOGICAL Ipilimumab 3 mg/kg IV
- BIOLOGICAL Nivolumab 6 mg/kg IV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 387 participants |
| Start Date | 2016-04-04 |
| Est. Completion | 2021-05-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02714218
The ClinicalTrials.gov registry entry for NCT02714218 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 387 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Nivolumab 3 mg/kg IV is the first listed.
NCT02714218 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02714218 about?
NCT02714218 is a clinical study titled "A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma". The purpose of this study is to evaluate two different dose combinations of nivolumab and ipilimumab in the treatment of melanoma.
What is the current status of trial NCT02714218?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 387 participants. The study started on 2016-04-04. Estimated completion is 2021-05-28.
What interventions are being tested in trial NCT02714218?
The interventions under investigation include: Nivolumab 3 mg/kg IV (BIOLOGICAL), Ipilimumab 1 mg/kg IV (BIOLOGICAL), Nivolumab 1 mg/kg IV (BIOLOGICAL), Ipilimumab 3 mg/kg IV (BIOLOGICAL), Nivolumab 6 mg/kg IV (BIOLOGICAL).
Who is sponsoring clinical trial NCT02714218?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.